{
    "clinical_study": {
        "@rank": "33689", 
        "brief_summary": {
            "textblock": "OBJECTIVES:\n\n      I.  Determine the efficacy and safety of gammalinolenic acid in the treatment of childhood\n      arthritis."
        }, 
        "brief_title": "Study of Gammalinolenic Acid for Juvenile Rheumatoid Arthritis", 
        "completion_date": "August 1999", 
        "condition": "Juvenile Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid", 
                "Arthritis, Juvenile Rheumatoid"
            ]
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled, cross over study\n      of 12 months duration.  Patients are stratified by type of juvenile rheumatoid arthritis\n      (systemic onset vs pauciarticular disease vs polyarticular disease).\n\n      Patients are randomized to receive either gammalinolenic acid (GLA) or placebo (safflower\n      seed oil) orally.  Parents are asked to maintain the child's usual diet over the course of\n      study.\n\n      Patients are followed at 3, 6, 9, and 12 months during study and at 6 months thereafter."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics--\n\n          -  Juvenile rheumatoid arthritis (systemic onset, pauciarticular disease, and\n             polyarticular disease)\n\n          -  Active synovitis\n\n        --Prior/Concurrent Therapy--\n\n          -  No more than 2 concurrent nonsteroidal antiinflammatory drugs\n\n          -  No more than 2 concurrent second line agents (e.g., D-penicillamine, oral or\n             injectable gold, antimalarials, methotrexate, sulfasalazine)\n\n          -  Must have started second line agent at least 3 months prior to study\n\n          -  Must be on stable doses of all medications for at least 1 month prior to study\n\n          -  Prior prednisone allowed if started at least 3 months prior to study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "15 Years", 
            "minimum_age": "1 Year"
        }, 
        "enrollment": "50", 
        "firstreceived_date": "October 18, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004420", 
            "org_study_id": "199/13314", 
            "secondary_id": [
                "UMASS-H-2703", 
                "UMASS-FDR001067"
            ]
        }, 
        "intervention": {
            "intervention_name": "gamma-Linolenic acid", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Efamol"
        }, 
        "keyword": [
            "arthritis & connective tissue diseases", 
            "juvenile rheumatoid arthritis", 
            "rare disease"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "overall_official": {
            "affiliation": "University of Massachusetts, Worcester", 
            "last_name": "Robert B. Zurier", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004420"
        }, 
        "source": "FDA Office of Orphan Products Development", 
        "sponsors": {
            "collaborator": {
                "agency": "University of Massachusetts, Worcester", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "FDA Office of Orphan Products Development", 
                "agency_class": "U.S. Fed"
            }
        }, 
        "start_date": "September 1994", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2000"
    }, 
    "geocoordinates": {}
}